Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445738 · ClinicalTrials.gov registry record · NA
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
A NA study of Breast Cancer and Breast Cancer Female, sponsored by Breast Cancer Trials, Australia and New Zealand.
- Recruiting
- Registry status
- NA
- Development phase
- 1,400
- Enrollment target
- 9
- Study locations
NCT06445738 is a NA study of Breast Cancer and Breast Cancer Female that is actively recruiting participants, run by Breast Cancer Trials, Australia and New Zealand. The registered enrollment target is 1,400 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (50% lower). The trial reports 9 study locations across 5 states.
The verdict
NCT06445738, a NA study of Breast Cancer and Breast Cancer Female, is actively recruiting participants, sponsored by Breast Cancer Trials, Australia and New Zealand.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,400 participants
- Enrollment target
- 9
- Study locations
Study Summary
The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the cancer coming back after surgery. The main question it aims to answer is: \* Will cancer come back in the same breast as the original cancer in patients who have surgery for their breast cancer, but who don't have radiotherapy afterwards because the results of an MRI before surgery showed favourable characteristics for not having radiotherapy.
Conditions Studied
Interventions
- RADIATION Arm A: Radiotherapy Omission
- OTHER Arm B: Standard Treatment
Study Locations (9)
New South Wales
- The Chris O'Brien Lifehouse - Camperdown
- Lake Macquarie Private Hospital - Gateshead
- Mater Hospital, Sydney - North Sydney
- Westmead Hospital - Westmead
Victoria
- Monash Cancer Centre (MMC Moorabbin) - Clayton
- The Royal Melbourne Hospital - Melbourne
California
- UCSF Breast Care Center - San Francisco
Texas
- Baylor St Luke's Medical Centre - Houston
South Australia
- Royal Adelaide Hospital - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2025-06-06 |
| Est. Completion | 2039-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445738
The ClinicalTrials.gov registry entry for NCT06445738 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (50% lower). The listed sponsor is Breast Cancer Trials, Australia and New Zealand, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Arm A: Radiotherapy Omission is the first listed.
NCT06445738 reports 9 study locations spanning 5 distinct geographic areas - top geographies include New South Wales, Victoria, California.
Frequently Asked Questions
What is clinical trial NCT06445738 about?
NCT06445738 is a clinical study titled "Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)". The PROSPECTIVE trial aims to find out if using the results of Magnetic Resonance Imaging (MRI) for early breast cancer can select people to not have radiotherapy and still have a low chance of the cancer coming back after surgery. The main question it aims to answer is: \* Will cancer come back i...
What is the current status of trial NCT06445738?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,400 participants. The study started on 2025-06-06. Estimated completion is 2039-06.
What conditions does trial NCT06445738 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Cancer Female.
What interventions are being tested in trial NCT06445738?
The interventions under investigation include: Arm A: Radiotherapy Omission (RADIATION), Arm B: Standard Treatment (OTHER).
Who is sponsoring clinical trial NCT06445738?
This trial is sponsored by Breast Cancer Trials, Australia and New Zealand, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445738 being conducted?
This trial has 9 study locations across California, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Improving Comprehensive Care of Cancer Patients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.